Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

San Diego-based gene-sequencing giant Illumina got tangled in the United States’ trade tensions Tuesday as China placed the ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Leerink Partners raised their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally ...

Puneet Souda, a research analyst for Leerink Partners, wrote in a research note Tuesday that Illumina’s inclusion on the list “appears more permanent posturing by China” rather than ...